Melanoma is an aggressive malignancy originating from pigment-producing melanocytes.
The development of targeted therapies (MAPK pathway inhibitors) and immunotherapies …

Non-coding RNAs (ncRNAs) have been implicated in most cellular functions. The disruption
of their function through somatic mutations, genomic imprinting, transcriptional and post …

Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic
benefits but the common emergence of drug resistance remains a challenge. We generated …

Oleuropein (Ole), a secoiridoid glucoside present in Olea europaea leaves, gained scientific
interest thanks to its several biological properties, including the anticancer one. We verified …

Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …

Accumulating evidence has indicated that microRNAs (miRNAs) play an important role in
the occurrence and progression of ovarian cancer (OC). However, the function of miRNAs …

Rationale: The mitogen-activated protein kinase pathway (MAPK) is one of the major cancer-
driving pathways found in non-small cell lung cancer (NSCLC) patients. ERK inhibitors …

Melanoma is the utmost fatal kind of skin neoplasms. Molecular changes occurring during
the pathogenic processes of initiation and progression of melanoma are diverse and include …

BRAF-mutated melanoma relapsing after targeted therapies is an aggressive disease with
unmet clinical need. Hence the need to identify novel combination therapies able to …

Long intergenic nonprotein coding RNA 518 (LINC00518) has been shown to promote
cancer cell growth and metastasis in some human tumors. Although it has been reported …